Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810

Summary

The primary objective is to evaluate the safety and tolerability of repeated doses of intravenously administered ARCT-810.

Timeline

Start

2022-10-17

Primary completion

2024-10-31

Completion

2024-10-31

Outcome

Outcome not reported

Stopped (Enrollment): “The study was terminated after the completion of Cohort 1 (0.3 mg/kg) due to slow enrollment in this placebo-controlled study.”

Drugs

Indications